PressSeptember 14, 2023 Second Phase 3 Study of MDMA-assisted Therapy Reports Positive Results, Paving Way for New Drug Application
PressSeptember 14, 2023 Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications
PressSeptember 14, 2023 Atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
PressSeptember 14, 2023 Beckley Waves Raises $3.3 Million Funding Round to Expand Safe and Legal Access To Psychedelic Therapies
PressSeptember 14, 2023 PharmaDrug Provides Development Update of Cepharanthine (PD-001) for Cancer and Infectious Disease
PressSeptember 13, 2023 Clearmind Medicine : Condensed Interim Consolidated Financial Statements – Form 6-K
PressSeptember 13, 2023 Psyched Wellness Lists Calm at All Central Market Locations, In the United States
PressSeptember 12, 2023 Psychedelic Drugs Market revenue to exceed USD 12 Billion by 2035, says Research Nester
PressSeptember 12, 2023 Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD
PressSeptember 12, 2023 BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
PressSeptember 12, 2023 Lucy Scientific Discovery Inc. Announces Acquisition of BlueSky Wellness Inc. in All-Stock Transaction
PressSeptember 12, 2023 Safe Supply and Origin Therapeutics Receive Conditional Approval for Listing on the CSE
PressSeptember 8, 2023 Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference – September 11-13, 2023
PressSeptember 7, 2023 Lucy Scientific Acquires High Times Intellectual Property, Including Existing Licensing Agreements in All-Stock Transaction
PressSeptember 7, 2023 The Healing Company Appoints Biotech Visionaries Dr. Linda Friedland and Dr. Peter Kash as Advisors
PressSeptember 7, 2023 Optimi Health Granted Amendment to Dealer’s Licence by Health Canada to Supply Special Access Program
PressSeptember 6, 2023 Awakn Life Sciences Submits Clinical Trial Application for Phase III Trial Of AWKN-P001
PressSeptember 6, 2023 Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
